3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Genitourinary
1
CNS
1
Conditions
Neoplasms by Site
3
Neoplasms
3
Lymphoma, Large-Cell, Anaplastic
3
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Hematologic Neoplasms
2
Carcinoma, Renal Cell
2
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Melanoma
1
Lymphoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Interventions
Cyclophosphamide
8
fludarabine
4
Rituximab
4
Melphalan
3
tetulomab tetraxetan lu-177
2
ponatinib
2
fludarabine phosphate
2
entrectinib
2
atezolizumab
2
alectinib
2
Whole-Body Irradiation
2
Vincristine
2
Tacrolimus
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Lutetium
2
Etoposide
2
Doxorubicin
2
Busulfan
2
Brentuximab Vedotin
2
Bortezomib
2
Bone Marrow Transplantation
2
trametinib
1
pertuzumab
1
penpulimab
1
pembrolizumab
1
ibritumomab tiuxetan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
alectinib
×
Lymphoid
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled